One glioblastoma treatment looks unlike anything else in cancer care: a wearable device that delivers electrical fields through the scalp. Known as Tumor Treating Fields (TTFields), and marketed as Optune, it's an option many glioblastoma patients are offered, and it often raises questions.
How it works TTFields use low-intensity, alternating electric fields delivered through adhesive patches (arrays) worn on the shaved scalp. These fields are tuned to interfere with cell division — the process tumor cells rely on to multiply. By disrupting the machinery cells use to split, the fields aim to slow tumor growth. The device is portable, carried in a small bag, and connected to the scalp arrays.
Where it fits TTFields are used for glioblastoma, typically added to maintenance temozolomide after the initial chemoradiation phase. In the key trial, adding TTFields to temozolomide improved survival compared with temozolomide alone. The catch is that, to get the benefit, the device generally needs to be worn a large portion of each day — adherence matters.
What daily life is like Living with TTFields takes adjustment. You wear the arrays continuously, changing them every few days (which involves re-shaving the scalp). The most common side effect is skin irritation under the arrays, which can usually be managed. Many people are self-conscious about wearing a visible device, and carrying the equipment takes getting used to. On the other hand, it's a treatment with relatively few of the systemic side effects of drugs.
Is it right for you? That's a genuinely personal decision to make with your team, weighing the survival benefit against the practical demands and the lifestyle impact. Some patients find the trade-off clearly worth it; others find the device burdensome. There's no wrong answer — it depends on your values and circumstances.
If TTFields are offered, ask about the expected benefit in your situation, the wear-time commitment, skin care, and how to fit the device into your daily life.